LQDA
HealthcareLiquidia Corporation · Biotechnology · $5B
What is Liquidia Corporation?
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for serious, underserved conditions. Headquartered in Morrisville, North Carolina, the company is building a commercial presence in pulmonary arterial hypertension.
Liquidia develops and commercializes inhaled and injectable therapies targeting pulmonary arterial hypertension, a rare and life-threatening disease. Its lead product, YUTREPIA, is an inhaled dry powder formulation of treprostinil designed to offer patients a more convenient delivery option. The company also distributes a generic treprostinil injection in the United States, giving it a dual commercial footprint as it scales its operations.
Liquidia was founded in 2018 and is headquartered in Morrisville, North Carolina.
- YUTREPIA — inhaled dry powder treprostinil for pulmonary arterial hypertension
- Generic treprostinil injection distributed across the United States
- Proprietary drug formulation and manufacturing capabilities
- Rare disease commercial infrastructure in the US market
Is LQDA a Good Stock to Buy?
UQS Score rates LQDA as Good overall, reflecting a company in active commercial growth with meaningful upside potential balanced by early-stage financial risks.
The Growth pillar stands out as the clearest strength — Liquidia is expanding its commercial footprint at a pace that places it well above many peers in the rare disease space. The Valuation pillar is rated Attractive, suggesting the market may not yet be fully pricing in the company's trajectory. The Risk pillar sits at Neutral, indicating manageable but real uncertainty.
The Quality pillar is rated Weak, which typically reflects the financial profile of a company still investing heavily ahead of profitability. Investors should weigh this alongside the Neutral Moat rating.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does LQDA pay dividends?
No — Liquidia Corporation does not currently pay a dividend.
Liquidia does not currently pay a dividend. This is consistent with its stage of development — the company is directing available capital toward commercializing YUTREPIA and expanding its market presence. Investors in early-stage biopharmaceutical companies typically expect returns through share price appreciation rather than income distributions.
When does LQDA report earnings?
Liquidia Corporation reports earnings on a quarterly cadence, typical for US-listed equities.
Each quarterly report provides an update on YUTREPIA's commercial uptake, generic treprostinil distribution, and the company's operating expense trajectory as it scales. Revenue trends and cash runway are the key metrics investors tend to focus on at this stage of growth.
For the most recent quarter's results and guidance commentary, visit Liquidia Corporation's investor relations page directly.
LQDA Price History
+1104.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
LQDA Long-term Outlook
Liquidia's Strong Growth pillar signals that the company's commercial ramp is gaining traction, with YUTREPIA representing a meaningful opportunity in the pulmonary arterial hypertension market. The Attractive Valuation label suggests the current price may leave room for appreciation if execution continues. However, the Weak Quality pillar is a reminder that the path to sustainable profitability carries execution risk, and the Neutral Risk profile reflects the inherent uncertainty of a company still in its early commercial phase.
Growth drivers
- Continued YUTREPIA adoption among pulmonary arterial hypertension patients
- Expansion of the generic treprostinil injection distribution network
- Potential label expansions or pipeline additions in rare cardiopulmonary diseases
Key risks
- Ongoing cash consumption ahead of profitability given the Weak Quality profile
- Competitive pressure from established therapies in the pulmonary hypertension space
- Regulatory or reimbursement hurdles that could slow YUTREPIA's commercial uptake
LQDA vs Peers
Liquidia operates in a competitive biopharmaceutical landscape alongside other specialty and rare disease-focused companies.
Dianthus focuses on complement-mediated rare diseases, targeting a different biological pathway than Liquidia's pulmonary arterial hypertension franchise.
Dyne is developing muscle disease therapies using its proprietary delivery platform, competing for rare disease investor attention rather than the same patient population.
Telix concentrates on targeted radiation therapies for cancer, giving it a distinct commercial and scientific profile compared to Liquidia's inhaled pulmonary therapies.
Frequently Asked Questions
What does Liquidia Corporation do?
Liquidia is a biopharmaceutical company that develops and commercializes treatments for pulmonary arterial hypertension, a rare and serious lung disease. Its lead product, YUTREPIA, is an inhaled dry powder therapy. The company also distributes a generic treprostinil injection in the United States.
Does LQDA pay dividends?
Liquidia does not pay a dividend. As a commercial-stage biopharmaceutical company, it reinvests available capital into growing its product portfolio and expanding its commercial infrastructure rather than returning cash to shareholders through income distributions.
When does LQDA report earnings?
Liquidia reports on a quarterly cadence, as is standard for US-listed companies. Each report typically covers YUTREPIA sales progress and operating expenses. For exact dates and the most recent results, check Liquidia's investor relations page.
Is LQDA a good stock to buy?
UQS Score rates LQDA as Good overall. The Growth pillar is Strong and Valuation is Attractive, which are positive signals. However, the Quality pillar is Weak, reflecting the financial profile typical of a company still scaling toward profitability. The full pillar breakdown is available to Pro members.
Is LQDA overvalued?
The UQS Valuation pillar for LQDA is rated Attractive, suggesting the stock may be reasonably priced relative to its growth profile. Valuation for early-stage biopharma companies is inherently forward-looking, so investors should review the complete analysis for context.
How does LQDA compare to its competitors?
Liquidia's closest comparables in the rare disease space include Dianthus Therapeutics, Dyne Therapeutics, and Telix Pharmaceuticals. Each targets different diseases and biological mechanisms. UQS Score provides side-by-side pillar comparisons for Pro members looking to evaluate these companies together.
What is LQDA's market cap bracket?
Liquidia Corporation is classified as a mid-cap company. This places it in a bracket where commercial traction is being established but the company has not yet reached the scale of large-cap pharmaceutical peers.
Who founded Liquidia Corporation?
Liquidia was founded in 2004, with its origins tied to research at the University of North Carolina at Chapel Hill. The company's founding team developed proprietary particle engineering technology that underpins its drug formulation approach. Detailed founding history is publicly available through the company's official disclosures.
Is LQDA a long-term quality investment?
As a long-term quality indicator, LQDA's profile is mixed. The Strong Growth and Attractive Valuation pillars are encouraging for investors with a longer horizon, but the Weak Quality pillar signals that financial durability is still developing. Pro members can view the full breakdown to assess fit with their criteria.
What is the main competitive advantage of Liquidia Corporation?
Liquidia's differentiation lies in its proprietary drug formulation technology and its focus on the inhaled delivery of treprostinil through YUTREPIA. This approach aims to offer pulmonary arterial hypertension patients a more convenient treatment option compared to existing alternatives, which is central to its commercial strategy.
What sector does LQDA belong to?
Liquidia Corporation operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses on rare cardiopulmonary diseases, a niche that tends to attract investors seeking high-growth opportunities in specialty drug development and commercialization.
Is LQDA a growth stock or value stock?
Based on UQS pillar labels, LQDA leans toward growth — the Growth pillar is rated Strong and Valuation is Attractive. This combination is often associated with companies where the market has not yet fully priced in the commercial opportunity, making it of interest to growth-oriented investors.
Unlock Full LQDA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact UQS pillar scores across all five dimensions
- ✓Access complete financial metrics and trend data
- ✓Compare LQDA side-by-side with rare disease peers
- ✓See valuation context relative to sector benchmarks
- ✓Get the full analyst-style quality breakdown in one view
Pro Analysis
LQDA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 64.5 | 58.7 | 43.0 | 100.0 | 56.6 | 70.7 | +0.1 |
| May 22, 2026 | 64.4 | 58.7 | 43.0 | 100.0 | 56.6 | 70.1 | 0.0 |
| May 21, 2026 | 64.4 | 58.7 | 43.0 | 100.0 | 56.6 | 70.2 | -2.7 |
| May 15, 2026 | 67.1 | 58.7 | 43.0 | 100.0 | 72.8 | 71.8 | -0.2 |
| May 13, 2026 | 67.3 | 58.8 | 43.0 | 100.0 | 72.8 | 72.9 | +0.1 |
| May 12, 2026 | 67.2 | 63.8 | 43.0 | 100.0 | 68.1 | 68.2 | +10.7 |
| Apr 2, 2026 | 56.5 | 16.7 | 43.0 | 100.0 | 43.8 | 100.0 | — |
LQDA — Pillar Breakdown
Quality
— 58.7/100 (25%)Liquidia Corporation shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 100.0/100 (20%)Liquidia Corporation is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 56.6/100 (15%)Liquidia Corporation maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 70.7/100 (15%)Liquidia Corporation trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 43/100 (25%)Liquidia Corporation possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for LQDA.
Score Composition
Financial Data
More Stock Analysis
How is the LQDA UQS Score Calculated?
The UQS (Unified Quality Score) for Liquidia Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Liquidia Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Liquidia Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.